The FDA-approved technology developed by HeartFlow can predict a patient's long-term risk of target vessel failure as well as more invasive treatments performed inside a cath lab. 

New data out of Germany suggest TMVR can offer intermediate-risk patients a safe alternative to surgery.

Ken Rosenfield, MD, of Massachusetts General Hospital, and William Gray, MD, of Lankenau Heart Institute, detailed the long-term impact of a key policy shift. 

Interventional cardiologists have been anticipating this news for quite some time. The device, the first of its kind, provides an alternative treatment option to repeat PCI or cardiac surgery for patients with coronary ISR.

Nearly 80% of Black and Hispanic adults said they never discussed PAD with a doctor, which vascular experts say is a major problem.

The doctor appealed the hospital's decision in hopes of returning to work, but that appeal was ultimately denied. 

According to Philips, this latest update makes the Azurion image-guided therapy platform more efficient than ever.

The study’s authors tracked data from nearly 16,000 patients who underwent PCI from 2010 to 2023. This is believed this to be the largest comparison of intravascular imaging-guided PCI and angiography-guided PCI to date.